Catamaran Bio
Catamaran Bio is developing novel, off-the-shelf CAR-NK cell therapies designed to treat a broad range of cancers, including solid tumors. The company's proprietary capabilities enable it to harness the natural cancer-fighting properties of NK cells and enhance and tailor their effectiveness with the power of synthetic biology and innovative non-viral cell engineering.
Sector
Biopharmaceuticals
Strategies
Capital
Status
Active
Website
catamaranbio.com
Related News
Catamaran Bio to present preclinical data at ASGCT Annual Meeting to support CAR-NK approach for solid tumors
Catamaran Bio appoints Cherry Thomas, MD, as Chief Medical Officer
Catamaran Bio appoints Frank Lee as Chair of its Board of Directors
Catamaran Bio expands collaboration for CAR-NK cell engineering with the University of Minnesota and secures an exclusive patent license to next generation manufacturing technologies
Catamaran Bio announces appointment of Michael DeRidder, PhD, as senior vice president, corporate strategy and new product planning
SofinnovaCapital
The Sofinnova Capital Strategy acts as a founding and lead investor in early-stage biopharma and medtech start-ups focusing on groundbreaking therapeutic technologies.
SofinnovaMD Start
The MD Start Strategy is Sofinnova’s in-house medtech accelerator. The team’s hands-on entrepreneurial expertise contributes to the platform's global leadership in company building.
SofinnovaCrossover
The Sofinnova Crossover Strategy supports ground-breaking innovations in later-stage biotech and medtech companies, enabling ambitious life sciences companies to reach their full potential.
SofinnovaIndustrial Biotech
Our Industrial Biotech Strategy seeks early-stage investments that will have a positive impact on sustainability in the chemicals, agriculture, food and materials sectors.
SofinnovaTelethon
The Sofinnova Telethon Strategy seeks early-stage projects to bring the best Italian science to the world stage.
SofinnovaDigital Medicine
The Sofinnova Digital Medicine Strategy backs early-stage startups at the intersection of biology, data and computation.
SofinnovaBiovelocita
The Sofinnova Biovelocita Strategy is dedicated entirely to the creation and acceleration of European biotech startups, in partnership with leading research organizations.